5 Most Promising Healthcare Stocks According to Analysts

3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Number of Hedge Fund Holders: 38

One-Year Average Price Estimate: $202.00

As of March 13, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was trading at around $135, while its one-year average price target stands at $202. This shows a significant upside potential for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) from the current levels.

At the end of the December quarter, 38 hedge funds had stakes in Jazz Pharmaceuticals plc (NASDAQ:JAZZ), according to Insider Monkey’s proprietary database. The total value of these stakes was about $1.3 billion. The most notable hedge fund stakeholder of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was Bernard Horn’s Polaris Capital Management with a $200 million stake.

Recently, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted Q4 results that missed analyst estimates for both income and revenue. However, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said it is expecting its 2023 revenue to come in the range of $3.675 billion to $3.875 billion, which was better than the consensus estimate of $3.76 billion.